Ratings Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 09:05:29 11/07/2025 pm IST			5-day change	1st Jan Change
7.046 ^EUR	-2.14%		-1.32%	-14.02%

09/07	EVOTEC : Deutsche Bank reiterates its Neutral rating	ZD
26/06	EVOTEC : Warburg Research remains its Buy rating	ZD

Summary: Evotec SE

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to MSCI, the company's ESG score for its industry is good.

Highlights: Evotec SE

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses: Evotec SE

The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings Chart: Evotec SE

Source: Surperformance

ESG chart: Evotec SE

Source: MSCI

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Global Valuation (Composite)	Capi.($)
EVOTEC SE	-	149.46Cr
LONZA GROUP AG		5.04TCr
BEONE MEDICINES LTD.		3TCr
CELLTRION, INC.		2.87TCr
IQVIA HOLDINGS INC.		2.86TCr
EUROFINS SCIENTIFIC SE		1.27TCr
ICON PUBLIC LIMITED COMPANY		1.21TCr
QIAGEN N.V.		1.05TCr
Average		2.18TCr
Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

AAA

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes